STOCK TITAN
  1. Home
  2. News
  3. NUVL

Nuvalent Inc - NUVL STOCK NEWS

IMPACT
SENTIMENT
NUVL : Nasdaq
Nuvalent Announces Pricing of Public Offering of Common Stock
offering
IMPACT
SENTIMENT
NUVL : Nasdaq
Nuvalent Announces Public Offering of Common Stock
offering
IMPACT
SENTIMENT
NUVL : Nasdaq
Nuvalent Reports Preliminary Phase 1 Clinical Data from ALKOVE-1 Trial that Support Best-In-Class Potential of NVL-655 for Patients with ALK-Positive NSCLC
clinical trial
IMPACT
SENTIMENT
NUVL : Nasdaq
Preliminary Phase 1 Dose-Escalation Data from ALKOVE-1 Trial of NVL-655 Demonstrated Activity in Heavily Pre-Treated Patients with ALK-Positive NSCLC and an ALK-Selective, TRK-Sparing Safety Profile
clinical trial
IMPACT
SENTIMENT
NUVL : Nasdaq
Nuvalent to Present Preliminary Data from ALKOVE-1 Phase 1/2 Clinical Trial of NVL-655 at 35th AACR-NCI-EORTC Symposium
conferences clinical trial
IMPACT
SENTIMENT
NUVL : Nasdaq
Nuvalent Initiates the Phase 2 Portion of ARROS-1 Clinical Trial for Patients with ROS1-Positive NSCLC and other Solid Tumors
clinical trial
IMPACT
SENTIMENT
NUVL : Nasdaq
Nuvalent to Participate in Upcoming September Investor Conferences
conferences
IMPACT
SENTIMENT
NUVL : Nasdaq
Nuvalent Highlights Pipeline Progress and Reports Second Quarter 2023 Financial Results
earnings
IMPACT
SENTIMENT
NUVL : Nasdaq
Nuvalent to Participate in Upcoming August Investor Conferences
conferences
IMPACT
SENTIMENT
NUVL : Nasdaq
Nuvalent to Participate in the TD Cowen 4th Annual Oncology Innovation Summit
conferences
Stock NUVL logo
Nuvalent Inc
Nasdaq:NUVL

NUVL Stock Data

Research and Development in Biotechnology
Professional, Scientific, and Technical Services

About NUVL

nuvalent is improving human health by developing breakthrough small molecule therapeutics that engage biological targets in new ways using cutting-edge chemical insights. by expanding the universe of targets that interact with small molecules, we are generating therapeutics with activities not previously possible, including modulation of ‘undruggable’ targets. our unique approach is leading to first-in-class and best-in-class small molecule therapeutics that will significantly impact patient’s lives.